-
公开(公告)号：US20120040906A1
公开(公告)日：2012-02-16
申请号：US13202482
申请日：2010-02-26
Applicant: Afshin Samali , Sanjeev Gupta
Inventor： Afshin Samali , Sanjeev Gupta
IPC: A61K38/02 , C40B30/04 , A61K31/7105 , G06F19/18 , C12Q1/68 , G01N33/68 , A61P9/00 , A61P9/04 , C07H21/02 , C07K14/47
CPC classification number: C12Q1/6883 , C12N15/111 , C12N2310/141 , C12N2320/11 , C12N2330/10 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G16B15/00 , G16B20/00 , G16B30/00
Abstract: MicroRNAs have been shown to be critically involved in control of cell survival and cell death decisions. By identifying microRNAs implicated in Endoplasmic Reticulum stress-induced cardiomyocyte apoptosis, it is envisaged that protein targets involved in same can be identified through specifically selected microRNAs. The microRNAs targeted are miR-351, miR-322, miR-125, miR-424 and miR-7a. Furthermore, the potential application of these identified proteins in the treatment of cardiovascular disease, in particular congestive heart failure, is disclosed.
Abstract translation: 已经显示MicroRNA严格参与控制细胞存活和细胞死亡决定。 通过鉴定涉及内质网应激诱导的心肌细胞凋亡的微小RNA，设想通过特异选择的微小RNA可以鉴定参与其中的蛋白质靶标。 靶向的miRNA是miR-351，miR-322，miR-125，miR-424和miR-7a。 此外，公开了这些鉴定的蛋白质在治疗心血管疾病，特别是充血性心力衰竭中的潜在应用。
-
公开(公告)号：US20100150877A1
公开(公告)日：2010-06-17
申请号：US12528610
申请日：2008-03-03
Applicant: Timothy O'Brien , Frank Barry , Aaron Liew Yie Loong , Afshin Samali , Angela Duffy
Inventor： Timothy O'Brien , Frank Barry , Aaron Liew Yie Loong , Afshin Samali , Angela Duffy
IPC: A61K38/17 , C12N5/074 , C07K14/46 , C07H21/04 , A61K35/12 , A61K31/7088 , C12Q1/02 , C07K16/18 , A61P9/00
Abstract: Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.
Abstract translation: 用于预测和治疗心血管疾病的骨桥蛋白本发明涉及内皮祖细胞（EPCs）和骨桥蛋白用于治疗心血管疾病或并发症的用途。 本发明还涉及使用EPC骨桥蛋白水平作为发展这些心血管并发症风险的标志物。 特别地，本发明提供了基于骨桥蛋白和编码骨桥蛋白的基因的组合物和方法。
-
公开(公告)号：US20080044376A1
公开(公告)日：2008-02-21
申请号：US10581856
申请日：2004-12-06
Applicant: Vicente R. Tur , Albert Martinus Van der Sloot , Margaret M. Mullally , Robbert H. Cool , Eva E. Szegezdi , Afshin Samali , Gregorio Fernandez-Ballester , Luis Serrano , Wilhelmus J. Ouax
Inventor： Vicente R. Tur , Albert Martinus Van der Sloot , Margaret M. Mullally , Robbert H. Cool , Eva E. Szegezdi , Afshin Samali , Gregorio Fernandez-Ballester , Luis Serrano , Wilhelmus J. Ouax
CPC classification number: G06F19/16 , C07K14/70575 , G06F19/22
Abstract: The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of the invention.
Abstract translation: 本发明涉及设计蛋白质，特别是细胞因子的新方法。 这些方法允许这种细胞因子的稳定化，以及它们对同源受体的选择性/特异性的修饰。 本发明还涉及通过本发明的方法设计的各种改性蛋白质。
-
公开(公告)号：US08323968B2
公开(公告)日：2012-12-04
申请号：US12528610
申请日：2008-03-03
Applicant: Timothy O'Brien , Frank Barry , Aaron Yie Loong Liew , Afshin Samali , Angela Duffy
Inventor： Timothy O'Brien , Frank Barry , Aaron Yie Loong Liew , Afshin Samali , Angela Duffy
Abstract: Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.
Abstract translation: 用于预测和治疗心血管疾病的骨桥蛋白本发明涉及内皮祖细胞（EPCs）和骨桥蛋白用于治疗心血管疾病或并发症的用途。 本发明还涉及使用EPC骨桥蛋白水平作为发展这些心血管并发症风险的标志物。 特别地，本发明提供了基于骨桥蛋白和编码骨桥蛋白的基因的组合物和方法。
-
Patent Agency Ranking
公开(公告)号：US07994281B2
公开(公告)日：2011-08-09
申请号：US10581856
申请日：2004-12-06
Applicant: Vicente R. Tur , Albert Martinus Van der Sloot , Margaret M. Mullally , Robbert H. Cool , Eva E. Szegezdi , Afshin Samali , Gregorio Fernandez-Ballester , Luis Serrano , Wilhelmus J. Quax
Inventor： Vicente R. Tur , Albert Martinus Van der Sloot , Margaret M. Mullally , Robbert H. Cool , Eva E. Szegezdi , Afshin Samali , Gregorio Fernandez-Ballester , Luis Serrano , Wilhelmus J. Quax
IPC: C07K14/52 , C07K14/525
CPC classification number: G06F19/16 , C07K14/70575 , G06F19/22
Abstract: The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of the invention.
Abstract translation: 本发明涉及设计蛋白质，特别是细胞因子的新方法。 这些方法允许这种细胞因子的稳定化，以及它们对同源受体的选择性/特异性的修饰。 本发明还涉及通过本发明的方法设计的各种改性蛋白质。
-
公开(公告)号：US20110165265A1
公开(公告)日：2011-07-07
申请号：US12808595
申请日：2008-12-17
Applicant: Afshin Samali
Inventor： Afshin Samali
CPC classification number: C07K14/70575 , A61K9/0019 , A61K33/24 , A61K38/191 , A61K2300/00
Abstract: The present invention relates to the use of a mutant TRAIL protein to treat various cancers in mammals. The invention provides a variant TRAIL protein, which has superior selectivity for the death receptor 5, for treating a mammal diagnosed with cancer.
Abstract translation: 本发明涉及使用突变型TRAIL蛋白来治疗哺乳动物中的各种癌症。 本发明提供了一种对死亡受体5具有优异选择性的变体TRAIL蛋白，用于治疗诊断为癌症的哺乳动物。
-
公开(公告)号：US20130280269A1
公开(公告)日：2013-10-24
申请号：US13702649
申请日：2011-06-08
Applicant: Afshin Samali , Sanjeev Gupta , Aysawaria Deepti
Inventor： Afshin Samali , Sanjeev Gupta , Aysawaria Deepti
IPC: C12N9/12
CPC classification number: C12N9/12 , C07K14/47 , C12N5/0018 , C12N2501/07 , C12N2510/02
Abstract: The present invention relates to methods that manipulate the level of interaction between the proteins Hsp70 and IRE1α. In particular, the invention relates to methods of manipulating this interaction in order to increase protein yield, and to methods of manipulating this interaction in order to treat diseases associated with abnormal apoptotic activity, including cancer and autoimmune diseases.
Abstract translation: 本发明涉及操纵蛋白质Hsp70和IRE1α之间的相互作用水平的方法。 特别地，本发明涉及操纵该相互作用以增加蛋白质产量的方法，以及操纵该相互作用的方法以便治疗与异常凋亡活性相关的疾病，包括癌症和自身免疫性疾病。
-
公开(公告)号：US20110262455A1
公开(公告)日：2011-10-27
申请号：US13123348
申请日：2009-10-09
Applicant: Afshin Samali , Eva Szegezdi , Devalingam Mahalingam , Alessandro Natoni
Inventor： Afshin Samali , Eva Szegezdi , Devalingam Mahalingam , Alessandro Natoni
IPC: A61K39/395 , A61P35/00 , A61K31/7088 , A61K38/17
CPC classification number: A61K45/06 , A61K31/7105 , A61K38/1709 , A61K38/177 , A61K38/191 , A61K39/395 , C12N15/113 , C12N2310/14 , A61K2300/00
Abstract: A method of treating a proliferative disorder, and a pharmaceutical composition for use in such a method, comprises administering to the patient a combination of an agonist of a death receptor and an antagonist of Egr-1. The death receptor agonist and the Egr-1 antagonist may be administered sequentially, separately or in combination
Abstract translation: 一种治疗增殖性疾病的方法和用于该方法的药物组合物包括向患者施用死亡受体的激动剂和Egr-1的拮抗剂的组合。 死亡受体激动剂和Egr-1拮抗剂可以顺序，单独或组合施用
-
公开(公告)号：US20110200552A1
公开(公告)日：2011-08-18
申请号：US12744069
申请日：2008-11-21
Applicant: Carlos Ricardo Rodrigues Dos Reis , Wilhelmus Johannes Quax , Afshin Samali , Eva Szegezdi , Robbert Hans Cool , Albert Martinus Van Der Sloot , Luis Serrano , Vicente Tur
Inventor： Carlos Ricardo Rodrigues Dos Reis , Wilhelmus Johannes Quax , Afshin Samali , Eva Szegezdi , Robbert Hans Cool , Albert Martinus Van Der Sloot , Luis Serrano , Vicente Tur
CPC classification number: C07K14/525 , A61K38/00
Abstract: The present invention relates to novel cytokines, which have a modified selectivity/specificity for their cognate receptors. In particular, the invention relates to a variant TRAIL protein, which has superior selectivity for the death receptor 4 (TRAIL-RI) over the death receptor 5 (TRAIL-R2). In addition, the invention relates to a variant TRAIL protein which exhibits superior selectivity for the death receptor 4 (TRAIL-R1) over the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4).
Abstract translation: 本发明涉及新的细胞因子，其对于其同源受体具有修饰的选择性/特异性。 特别地，本发明涉及在死亡受体5（TRAIL-R2）上对死亡受体4（TRAIL-RI）具有优异选择性的变体TRAIL蛋白质。 此外，本发明涉及对诱饵受体DcR1（TRAIL-R3）和DcR2（TRAIL-R4）相对于死亡受体4（TRAIL-R1）具有优异选择性的变体TRAIL蛋白。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.013 seconds)
